C-terminal amidation of PACAP-38 and PACAP-27 is dispensable for biological activity at the PAC1 receptor

• Published in: Peptides (New York, N.Y. : 1980) N.Y. : 1980), 2016-05, Vol.79, p.39-48
• Main Authors: Emery, Andrew C., Alvarez, Ryan A., Abboud, Philip, Xu, Wenqin, Westover, Craig D., Eiden, Maribeth V., Eiden, Lee E.
• Format: Article
• Language: English
• Subjects: Amidation; Amides - pharmacology; Amino Acid Sequence; Animals; Cyclic AMP; Cyclic AMP - metabolism; HEK293 Cells; Humans; Nervous system; Neuropeptide; PAC1 receptor; PACAP; Pituitary Adenylate Cyclase-Activating Polypeptide - pharmacology; Pituitary Adenylate Cyclase-Activating Polypeptide - physiology; Rats; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I - physiology; Second Messenger Systems
• ISSN: 0196-9781; 1873-5169
• DOI: 10.1016/j.peptides.2016.03.003

•In vivo PACAP is a C-terminally α-amidated neuropeptide of 27 or 38 residues.•PACAP does not require α-amidation to activate the rat or human PAC1 receptor.•Amidation of PACAP is also dispensable for neuroendocrine cell differentiation. PACAP-27 and PACAP-38 are the exclusive physiological ligands for the mammalian PAC1 receptor. The role of C-terminal amidation of these ligands at that receptor was examined in neuroendocrine cells expressing the PAC1 receptor endogenously and in non-neuroendocrine cells in which the human and rat PAC1 receptors were expressed from stable single-copy genes driven by the CMV promoter, providing stoichiometrically appropriate levels of this Gs-coupled GPCR in order to examine the potency and intrinsic activity of PACAP ligands and their des-amidated congeners. We found that replacement of the C-terminal glycine residues of PACAP-27 and -38 with a free acid; or extension of either peptide with the two to three amino acids normally found at these positions in PACAP processing intermediates in vivo following endoproteolytic cleavage and after exoproteolytic trimming and glycine-directed amidated, were equivalent in potency to the fully processed peptides in a variety of cell-based assays. These included real-time monitoring of cyclic AMP generation in both NS-1 neuroendocrine cells and non-neuroendocrine HEK293 cells; PKA-dependent gene activation in HEK293 cells; and neuritogenesis and cell growth arrest in NS-1 cells. The specific implications for the role of amidation in arming of secretin-related neuropeptides for biological function, and the general implications for neuropeptide-based delivery in the context of gene therapy, are discussed.